Institut De Recherches Cliniques De Montreal

Xiphos Systems Corp, based in Montréal, Québec, specializes in providing a range of products and solutions tailored for various applications. The company offers a diverse lineup of products, including the Q7, Q8, Q8J, Q8RF camera boards, Q7 ACS, Q8 SDR Dock, and Q8J SDR Daughterboard, among others. These products are designed to cater to applications in RF ISR, EO-science, space science, launch communications, and beyond. In addition to its product offerings, Xiphos Systems Corp is dedicated to providing custom solutions for its clientele, ensuring that specific needs and requirements are addressed effectively. The company's commitment to innovation and excellence is evident in its focus on delivering high-quality products and services, making it a reliable partner for businesses seeking cutting-edge technology solutions. Generated from the website content

Abich Inc is a company located in Montréal, Québec, utilizing the IP address 83.137.232.137 for its web server operations. Their presence indicates an engagement in digital services, though specific offerings are not detailed in the provided information. The mention of the default web server page suggests that Abich Inc may be in the initial stages of establishing their online identity. This detail hints at potential developments in their digital presence and services in the future. Generated from the website

Alethia Biotherapeutics Inc, based in Montréal, QC, is focused on developing innovative cancer therapies, particularly targeting epithelial to mesenchymal transition (EMT) to combat chemotherapy resistance and metastatic tumor invasion. Their lead product, AB16B5, is a humanized IgG2 monoclonal antibody designed to inhibit EMT, showing promising preclinical results in enhancing chemotherapy response and reducing tumor invasion. The company has received FDA authorization to initiate Phase 2 development for AB16B5, marking a significant milestone in its research efforts. Alethia Biotherapeutics is set to present its findings at the Annual ASCO Meeting, highlighting the potential of their EMT inhibitor in treating metastatic non-small cell lung cancer. Generated from the website